1
|
Rosigkeit S, Kruchem M, Thies D, Kreft A, Eichler E, Boegel S, Jansky S, Siegl D, Kaps L, Pickert G, Haehnel P, Kindler T, Hartwig UF, Guerra C, Barbacid M, Schuppan D, Bockamp E. Definitive evidence for Club cells as progenitors for mutant Kras/Trp53-deficient lung cancer. Int J Cancer 2021; 149:1670-1682. [PMID: 34331774 DOI: 10.1002/ijc.33756] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Revised: 07/10/2021] [Accepted: 07/14/2021] [Indexed: 12/30/2022]
Abstract
Accumulating evidence suggests that both the nature of oncogenic lesions and the cell-of-origin can strongly influence cancer histopathology, tumor aggressiveness and response to therapy. Although oncogenic Kras expression and loss of Trp53 tumor suppressor gene function have been demonstrated to initiate murine lung adenocarcinomas (LUADs) in alveolar type II (AT2) cells, clear evidence that Club cells, representing the second major subset of lung epithelial cells, can also act as cells-of-origin for LUAD is lacking. Equally, the exact anatomic location of Club cells that are susceptible to Kras transformation and the resulting tumor histotype remains to be established. Here, we provide definitive evidence for Club cells as progenitors for LUAD. Using in vivo lineage tracing, we find that a subset of Kras12V -expressing and Trp53-deficient Club cells act as precursors for LUAD and we define the stepwise trajectory of Club cell-initiated tumors leading to lineage marker conversion and aggressive LUAD. Our results establish Club cells as cells-of-origin for LUAD and demonstrate that Club cell-initiated tumors have the potential to develop aggressive LUAD.
Collapse
Affiliation(s)
- Sebastian Rosigkeit
- Institute of Translational Immunology (TIM), University Medical Center, Johannes Gutenberg-University, Mainz, Germany
| | - Marie Kruchem
- Institute of Translational Immunology (TIM), University Medical Center, Johannes Gutenberg-University, Mainz, Germany
| | - Dorothe Thies
- Institute of Translational Immunology (TIM), University Medical Center, Johannes Gutenberg-University, Mainz, Germany
| | - Andreas Kreft
- Institute of Pathology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany
| | - Emma Eichler
- Institute of Translational Immunology (TIM), University Medical Center, Johannes Gutenberg-University, Mainz, Germany
| | - Sebastian Boegel
- Department of Internal Medicine, University Center of Autoimmunity, University Medical Center, Johannes Gutenberg-University, Mainz, Germany
| | - Sandrine Jansky
- Institute of Translational Immunology (TIM), University Medical Center, Johannes Gutenberg-University, Mainz, Germany
| | - Dominik Siegl
- Institute of Translational Immunology (TIM), University Medical Center, Johannes Gutenberg-University, Mainz, Germany
| | - Leonard Kaps
- Institute of Translational Immunology (TIM), University Medical Center, Johannes Gutenberg-University, Mainz, Germany
| | - Geethanjali Pickert
- Institute of Translational Immunology (TIM), University Medical Center, Johannes Gutenberg-University, Mainz, Germany
| | - Patricia Haehnel
- III. Department of Medicine Hematology, Internal Oncology and Pneumology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany
| | - Thomas Kindler
- III. Department of Medicine Hematology, Internal Oncology and Pneumology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany
| | - Udo F Hartwig
- Research Center for Immunotherapy, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.,III. Department of Medicine Hematology, Internal Oncology and Pneumology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany
| | - Carmen Guerra
- Experimental Oncology, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain
| | - Mariano Barbacid
- Experimental Oncology, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain
| | - Detlef Schuppan
- Institute of Translational Immunology (TIM), University Medical Center, Johannes Gutenberg-University, Mainz, Germany.,Research Center for Immunotherapy, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.,Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Ernesto Bockamp
- Institute of Translational Immunology (TIM), University Medical Center, Johannes Gutenberg-University, Mainz, Germany.,Research Center for Immunotherapy, University Medical Center, Johannes Gutenberg-University, Mainz, Germany
| |
Collapse
|
2
|
Bogucka K, Marini F, Rosigkeit S, Schloeder J, Jonuleit H, David K, Schlackow M, Rajalingam K. ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis. Cancer Gene Ther 2020; 28:359-374. [PMID: 33070159 DOI: 10.1038/s41417-020-00245-w] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2020] [Revised: 09/18/2020] [Accepted: 10/02/2020] [Indexed: 12/26/2022]
Abstract
KRAS is one of the most frequently mutated oncogenes, especially in lung cancers. Targeting of KRAS directly or the downstream effector signaling machinery is of prime interest in treating lung cancers. Here, we uncover that ERK3, a ubiquitously expressed atypical MAPK, is required for KRAS-mediated NSCLC tumors. ERK3 is highly expressed in lung cancers, and oncogenic KRAS led to the activation and stabilization of the ERK3 protein. In particular, phosphorylation of serine 189 in the activation motif of ERK3 is significantly increased in lung adenocarcinomas in comparison to adjacent normal controls in patients. Loss of ERK3 prevents the anchorage-independent growth of KRAS G12C-transformed human bronchial epithelial cells. We further find that loss of ERK3 reduces the oncogenic growth of KRAS G12C-driven NSCLC tumors in vivo and that the kinase activity of ERK3 is required for KRAS-driven oncogenesis in vitro. Our results demonstrate an obligatory role for ERK3 in NSCLC tumor progression and suggest that ERK3 kinase inhibitors can be pursued for treating KRAS G12C-driven tumors.
Collapse
Affiliation(s)
- Katarzyna Bogucka
- Cell Biology Unit, University Medical Center of the Johannes Gutenberg University Mainz, 55131, Mainz, Germany
| | - Federico Marini
- Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, 55131, Mainz, Germany.,Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University Mainz, 55131, Mainz, Germany
| | - Sebastian Rosigkeit
- Cell Biology Unit, University Medical Center of the Johannes Gutenberg University Mainz, 55131, Mainz, Germany
| | - Janine Schloeder
- Department of Dermatology of the University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
| | - Helmut Jonuleit
- Department of Dermatology of the University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
| | | | | | - Krishnaraj Rajalingam
- Cell Biology Unit, University Medical Center of the Johannes Gutenberg University Mainz, 55131, Mainz, Germany. .,University Cancer Center Mainz, University Medical Center Mainz, Mainz, Germany.
| |
Collapse
|
3
|
Bockamp E, Rosigkeit S, Siegl D, Schuppan D. Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology. Cells 2020; 9:E2102. [PMID: 32942725 PMCID: PMC7565449 DOI: 10.3390/cells9092102] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2020] [Revised: 09/07/2020] [Accepted: 09/11/2020] [Indexed: 02/06/2023] Open
Abstract
Cancer immunotherapy utilizes the immune system to fight cancer and has already moved from the laboratory to clinical application. However, and despite excellent therapeutic outcomes in some hematological and solid cancers, the regular clinical use of cancer immunotherapies reveals major limitations. These include the lack of effective immune therapy options for some cancer types, unresponsiveness to treatment by many patients, evolving therapy resistance, the inaccessible and immunosuppressive nature of the tumor microenvironment (TME), and the risk of potentially life-threatening immune toxicities. Given the potential of nanotechnology to deliver, enhance, and fine-tune cancer immunotherapeutic agents, the combination of cancer immunotherapy with nanotechnology can overcome some of these limitations. In this review, we summarize innovative reports and novel strategies that successfully combine nanotechnology and cancer immunotherapy. We also provide insight into how nanoparticular combination therapies can be used to improve therapy responsiveness, to reduce unwanted toxicity, and to overcome adverse effects of the TME.
Collapse
Affiliation(s)
- Ernesto Bockamp
- Institute of Translational Immunology, University Medical Center, Johannes Gutenberg University Mainz, 55131 Mainz, Germany; (E.B.); (S.R.); (D.S.)
- Research Center for Immunotherapy, University Medical Center, Johannes Gutenberg University Mainz, 55131 Mainz, Germany
| | - Sebastian Rosigkeit
- Institute of Translational Immunology, University Medical Center, Johannes Gutenberg University Mainz, 55131 Mainz, Germany; (E.B.); (S.R.); (D.S.)
- Research Center for Immunotherapy, University Medical Center, Johannes Gutenberg University Mainz, 55131 Mainz, Germany
| | - Dominik Siegl
- Institute of Translational Immunology, University Medical Center, Johannes Gutenberg University Mainz, 55131 Mainz, Germany; (E.B.); (S.R.); (D.S.)
- Research Center for Immunotherapy, University Medical Center, Johannes Gutenberg University Mainz, 55131 Mainz, Germany
| | - Detlef Schuppan
- Institute of Translational Immunology, University Medical Center, Johannes Gutenberg University Mainz, 55131 Mainz, Germany; (E.B.); (S.R.); (D.S.)
- Research Center for Immunotherapy, University Medical Center, Johannes Gutenberg University Mainz, 55131 Mainz, Germany
- Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
| |
Collapse
|
4
|
Pickert G, Wirtz S, Matzner J, Ashfaq-Khan M, Heck R, Rosigkeit S, Thies D, Surabattula R, Ehmann D, Wehkamp J, Aslam M, He G, Weigert A, Foerster F, Klotz L, Frick JS, Becker C, Bockamp E, Schuppan D. Wheat Consumption Aggravates Colitis in Mice via Amylase Trypsin Inhibitor-mediated Dysbiosis. Gastroenterology 2020; 159:257-272.e17. [PMID: 32251667 DOI: 10.1053/j.gastro.2020.03.064] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/28/2018] [Revised: 03/06/2020] [Accepted: 03/26/2020] [Indexed: 12/18/2022]
Abstract
BACKGROUND & AIMS Wheat has become the world's major staple and its consumption correlates with prevalence of noncommunicable disorders such as inflammatory bowel diseases. Amylase trypsin inhibitors (ATIs), a component of wheat, activate the intestine's innate immune response via toll-like receptor 4 (TLR4). We investigated the effects of wheat and ATIs on severity of colitis and fecal microbiota in mice. METHODS C57BL/6 wild-type and Tlr4-/- mice were fed wheat- or ATI-containing diets or a wheat-free (control) diet and then given dextran sodium sulfate to induce colitis; we also studied Il10-/- mice, which develop spontaneous colitis. Changes in fecal bacteria were assessed by taxa-specific quantitative polymerase chain reaction and 16S ribosomal RNA metagenomic sequencing. Feces were collected from mice on wheat-containing, ATI-containing, control diets and transplanted to intestines of mice with and without colitis on control or on ATI-containing diets. Intestinal tissues were collected and analyzed by histology, immunohistochemistry, and flow cytometry. Bacteria with reported immunomodulatory effects were incubated with ATIs and analyzed in radial diffusion assays. RESULTS The wheat- or ATI-containing diets equally increased inflammation in intestinal tissues of C57BL/6 mice with colitis, compared with mice on control diets. The ATI-containing diet promoted expansion of taxa associated with development of colitis comparable to the wheat-containing diet. ATIs inhibited proliferation of specific human commensal bacteria in radial diffusion assays. Transplantation of microbiota from feces of mice fed the wheat- or ATI-containing diets to intestines of mice on control diets increased the severity of colitis in these mice. The ATI-containing diet did not increase the severity of colitis in Tlr4-/- mice. CONCLUSIONS Consumption of wheat or wheat ATIs increases intestinal inflammation in mice with colitis, via TLR4, and alters their fecal microbiota. Wheat-based, ATI-containing diets therefore activate TLR4 signaling and promote intestinal dysbiosis.
Collapse
Affiliation(s)
- Geethanjali Pickert
- Institute of Translational Immunology, Univ. Medical Center, Johannes Gutenberg University Mainz, Germany; Research Center for Immunotherapy, Univ. Medical Center, Johannes Gutenberg University Mainz, Germany
| | - Stefan Wirtz
- Department of Medicine 1, Friedrich-Alexander-University, Erlangen, Germany
| | - Johannes Matzner
- Institute of Translational Immunology, Univ. Medical Center, Johannes Gutenberg University Mainz, Germany; Research Center for Immunotherapy, Univ. Medical Center, Johannes Gutenberg University Mainz, Germany
| | - Muhammad Ashfaq-Khan
- Institute of Translational Immunology, Univ. Medical Center, Johannes Gutenberg University Mainz, Germany; Research Center for Immunotherapy, Univ. Medical Center, Johannes Gutenberg University Mainz, Germany
| | - Rosario Heck
- Institute of Translational Immunology, Univ. Medical Center, Johannes Gutenberg University Mainz, Germany; Research Center for Immunotherapy, Univ. Medical Center, Johannes Gutenberg University Mainz, Germany
| | - Sebastian Rosigkeit
- Institute of Translational Immunology, Univ. Medical Center, Johannes Gutenberg University Mainz, Germany; Research Center for Immunotherapy, Univ. Medical Center, Johannes Gutenberg University Mainz, Germany
| | - Dorothe Thies
- Institute of Translational Immunology, Univ. Medical Center, Johannes Gutenberg University Mainz, Germany; Research Center for Immunotherapy, Univ. Medical Center, Johannes Gutenberg University Mainz, Germany
| | - Rambabu Surabattula
- Institute of Translational Immunology, Univ. Medical Center, Johannes Gutenberg University Mainz, Germany; Research Center for Immunotherapy, Univ. Medical Center, Johannes Gutenberg University Mainz, Germany
| | - Dirk Ehmann
- Department of Internal Medicine 1, University Hospital Tübingen, Germany
| | - Jan Wehkamp
- Department of Internal Medicine 1, University Hospital Tübingen, Germany
| | - Misbah Aslam
- Institute of Translational Immunology, Univ. Medical Center, Johannes Gutenberg University Mainz, Germany; Research Center for Immunotherapy, Univ. Medical Center, Johannes Gutenberg University Mainz, Germany
| | - Guiwei He
- Department of Medicine 1, Friedrich-Alexander-University, Erlangen, Germany
| | - Andreas Weigert
- Institute of Biochemistry I, Faculty of Medicine, Goethe University Frankfurt, Frankfurt, Germany
| | - Friedrich Foerster
- Institute of Translational Immunology, Univ. Medical Center, Johannes Gutenberg University Mainz, Germany; Research Center for Immunotherapy, Univ. Medical Center, Johannes Gutenberg University Mainz, Germany; Department of Internal Medicine I, University Medical Center, Johannes Gutenberg University Mainz, Germany
| | - Luisa Klotz
- Department of Neurology, University Hospital Muenster, Muenster, Germany
| | - Julia-Stefanie Frick
- Department for Medical Microbiology and Hygiene, Interfaculty Institute for Microbiology and Infection Medicine, University of Tübingen, Germany
| | - Christoph Becker
- Department of Medicine 1, Friedrich-Alexander-University, Erlangen, Germany
| | - Ernesto Bockamp
- Institute of Translational Immunology, Univ. Medical Center, Johannes Gutenberg University Mainz, Germany; Research Center for Immunotherapy, Univ. Medical Center, Johannes Gutenberg University Mainz, Germany
| | - Detlef Schuppan
- Institute of Translational Immunology, Univ. Medical Center, Johannes Gutenberg University Mainz, Germany; Research Center for Immunotherapy, Univ. Medical Center, Johannes Gutenberg University Mainz, Germany; Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
| |
Collapse
|
5
|
Yurugi H, Zhuang Y, Siddiqui FA, Liang H, Rosigkeit S, Zeng Y, Abou-Hamdan H, Bockamp E, Zhou Y, Abankwa D, Zhao W, Désaubry L, Rajalingam K. A subset of flavaglines inhibits KRAS nanoclustering and activation. J Cell Sci 2020; 133:jcs244111. [PMID: 32501281 DOI: 10.1242/jcs.244111] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2020] [Accepted: 04/30/2020] [Indexed: 08/31/2023] Open
Abstract
The RAS oncogenes are frequently mutated in human cancers and among the three isoforms (KRAS, HRAS and NRAS), KRAS is the most frequently mutated oncogene. Here, we demonstrate that a subset of flavaglines, a class of natural anti-tumour drugs and chemical ligands of prohibitins, inhibit RAS GTP loading and oncogene activation in cells at nanomolar concentrations. Treatment with rocaglamide, the first discovered flavagline, inhibited the nanoclustering of KRAS, but not HRAS and NRAS, at specific phospholipid-enriched plasma membrane domains. We further demonstrate that plasma membrane-associated prohibitins directly interact with KRAS, phosphatidylserine and phosphatidic acid, and these interactions are disrupted by rocaglamide but not by the structurally related flavagline FL1. Depletion of prohibitin-1 phenocopied the rocaglamide-mediated effects on KRAS activation and stability. We also demonstrate that flavaglines inhibit the oncogenic growth of KRAS-mutated cells and that treatment with rocaglamide reduces non-small-cell lung carcinoma (NSCLC) tumour nodules in autochthonous KRAS-driven mouse models without severe side effects. Our data suggest that it will be promising to further develop flavagline derivatives as specific KRAS inhibitors for clinical applications.
Collapse
Affiliation(s)
- Hajime Yurugi
- Cell Biology Unit, University Medical Center Mainz, Johannes Gutenberg University, D 55131 Mainz, Germany
| | - Yinyin Zhuang
- School of Chemical and Biomedical Engineering, Nanyang Technological University, 637457 Singapore
| | - Farid A Siddiqui
- Turku Centre for Biotechnology, Åbo Akademi University, Tykistökatu 6B, 20520 Turku, Finland
| | - Hong Liang
- Department of Integrative Biology and Pharmacology, Mcgovern Medical School, UT Health, 6431 Fannin St. MSE R382, Houston, TX 77030, USA
| | - Sebastian Rosigkeit
- Cell Biology Unit, University Medical Center Mainz, Johannes Gutenberg University, D 55131 Mainz, Germany
| | - Yongpeng Zeng
- School of Chemical and Biomedical Engineering, Nanyang Technological University, 637457 Singapore
| | - Hussein Abou-Hamdan
- Therapeutic Laboratory of Cardio-Oncology and Medicinal Chemistry (FRE 2033), CNRS, University of Strasbourg, 4 rue Blaise Pascal, CS 90032, 67081 Strasbourg, France
| | - Ernesto Bockamp
- Institute for Translational Immunology and Research Center for Immunotherapy, University Medical Center, Johannes Gutenberg University, D 55131 Mainz, Germany
| | - Yong Zhou
- Department of Integrative Biology and Pharmacology, Mcgovern Medical School, UT Health, 6431 Fannin St. MSE R382, Houston, TX 77030, USA
| | - Daniel Abankwa
- Turku Centre for Biotechnology, Åbo Akademi University, Tykistökatu 6B, 20520 Turku, Finland
- Cancer Cell Biology and Drug Discovery Group, Life Sciences Research Unit University of Luxembourg, L 4362 Esch-sur-Alzette, Luxembourg
| | - Wenting Zhao
- School of Chemical and Biomedical Engineering, Nanyang Technological University, 637457 Singapore
| | - Laurent Désaubry
- Therapeutic Laboratory of Cardio-Oncology and Medicinal Chemistry (FRE 2033), CNRS, University of Strasbourg, 4 rue Blaise Pascal, CS 90032, 67081 Strasbourg, France
| | - Krishnaraj Rajalingam
- Cell Biology Unit, University Medical Center Mainz, Johannes Gutenberg University, D 55131 Mainz, Germany
- University Cancer Center Mainz, University Medical Center Mainz, D 55131 Mainz, Germany
| |
Collapse
|
6
|
Bogucka K, Pompaiah M, Marini F, Binder H, Harms G, Kaulich M, Klein M, Michel C, Radsak MP, Rosigkeit S, Grimminger P, Schild H, Rajalingam K. ERK3/MAPK6 controls IL-8 production and chemotaxis. eLife 2020; 9:52511. [PMID: 32314963 PMCID: PMC7192585 DOI: 10.7554/elife.52511] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Accepted: 04/17/2020] [Indexed: 12/11/2022] Open
Abstract
ERK3 is a ubiquitously expressed member of the atypical mitogen activated protein kinases (MAPKs) and the physiological significance of its short half-life remains unclear. By employing gastrointestinal 3D organoids, we detect that ERK3 protein levels steadily decrease during epithelial differentiation. ERK3 is not required for 3D growth of human gastric epithelium. However, ERK3 is stabilized and activated in tumorigenic cells, but deteriorates over time in primary cells in response to lipopolysaccharide (LPS). ERK3 is necessary for production of several cellular factors including interleukin-8 (IL-8), in both, normal and tumorigenic cells. Particularly, ERK3 is critical for AP-1 signaling through its interaction and regulation of c-Jun protein. The secretome of ERK3-deficient cells is defective in chemotaxis of neutrophils and monocytes both in vitro and in vivo. Further, knockdown of ERK3 reduces metastatic potential of invasive breast cancer cells. We unveil an ERK3-mediated regulation of IL-8 and epithelial secretome for chemotaxis.
Collapse
Affiliation(s)
- Katarzyna Bogucka
- Cell Biology Unit, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Malvika Pompaiah
- Cell Biology Unit, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Federico Marini
- Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.,Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Harald Binder
- Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.,Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center - University of Freiburg, Freiburg, Germany
| | - Gregory Harms
- Cell Biology Unit, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.,Departments of Biology and Physics, Wilkes University, Wilkes Barre, United States
| | - Manuel Kaulich
- Gene Editing Group, Institute of Biochemistry II, Goethe University, Frankfurt, Germany.,Frankfurt Cancer Institute, Frankfurt, Germany
| | - Matthias Klein
- Institute of Immunology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Christian Michel
- Department of Hematology, Medical Oncology, & Pneumology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Markus P Radsak
- Department of Hematology, Medical Oncology, & Pneumology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Sebastian Rosigkeit
- Cell Biology Unit, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Peter Grimminger
- Department of General, Visceral- and Transplant Surgery, University Medical Center, Mainz, Germany
| | - Hansjörg Schild
- Institute of Immunology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Krishnaraj Rajalingam
- Cell Biology Unit, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.,University Cancer Center Mainz, University Medical Center Mainz, Mainz, Germany
| |
Collapse
|
7
|
Luther J, Yorgan TA, Rolvien T, Ulsamer L, Koehne T, Liao N, Keller D, Vollersen N, Teufel S, Neven M, Peters S, Schweizer M, Trumpp A, Rosigkeit S, Bockamp E, Mundlos S, Kornak U, Oheim R, Amling M, Schinke T, David JP. Wnt1 is an Lrp5-independent bone-anabolic Wnt ligand. Sci Transl Med 2019; 10:10/466/eaau7137. [PMID: 30404864 DOI: 10.1126/scitranslmed.aau7137] [Citation(s) in RCA: 58] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2018] [Accepted: 10/15/2018] [Indexed: 12/14/2022]
Abstract
WNT1 mutations in humans are associated with a new form of osteogenesis imperfecta and with early-onset osteoporosis, suggesting a key role of WNT1 in bone mass regulation. However, the general mode of action and the therapeutic potential of Wnt1 in clinically relevant situations such as aging remain to be established. Here, we report the high prevalence of heterozygous WNT1 mutations in patients with early-onset osteoporosis. We show that inactivation of Wnt1 in osteoblasts causes severe osteoporosis and spontaneous bone fractures in mice. In contrast, conditional Wnt1 expression in osteoblasts promoted rapid bone mass increase in developing young, adult, and aged mice by rapidly increasing osteoblast numbers and function. Contrary to current mechanistic models, loss of Lrp5, the co-receptor thought to transmit extracellular WNT signals during bone mass regulation, did not reduce the bone-anabolic effect of Wnt1, providing direct evidence that Wnt1 function does not require the LRP5 co-receptor. The identification of Wnt1 as a regulator of bone formation and remodeling provides the basis for development of Wnt1-targeting drugs for the treatment of osteoporosis.
Collapse
Affiliation(s)
- Julia Luther
- Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Timur Alexander Yorgan
- Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Tim Rolvien
- Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Lorenz Ulsamer
- Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Till Koehne
- Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.,Department of Orthodontics, University Medical Center Hamburg-Eppendorf, D 20246 Hamburg, Germany
| | - Nannan Liao
- Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Daniela Keller
- Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Nele Vollersen
- Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Stefan Teufel
- Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Mona Neven
- Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Stephanie Peters
- Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Michaela Schweizer
- Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, D 20251 Hamburg, Germany
| | - Andreas Trumpp
- Division of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ), D 69120 Heidelberg, Germany
| | - Sebastian Rosigkeit
- Institute for Translational Immunology and Research Center for Immunotherapy, University Medical Center, Johannes Gutenberg University, D 55131 Mainz, Germany
| | - Ernesto Bockamp
- Institute for Translational Immunology and Research Center for Immunotherapy, University Medical Center, Johannes Gutenberg University, D 55131 Mainz, Germany
| | - Stefan Mundlos
- Institute of Medical Genetics and Human Genetics, Charité-Universitätsmedizin Berlin, D 13353 Berlin, Germany.,Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, D 13353 Berlin, Germany.,Max Planck Institute for Molecular Genetics, D 14195 Berlin, Germany
| | - Uwe Kornak
- Institute of Medical Genetics and Human Genetics, Charité-Universitätsmedizin Berlin, D 13353 Berlin, Germany.,Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, D 13353 Berlin, Germany.,Max Planck Institute for Molecular Genetics, D 14195 Berlin, Germany
| | - Ralf Oheim
- Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Michael Amling
- Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
| | - Thorsten Schinke
- Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
| | - Jean-Pierre David
- Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
| |
Collapse
|
8
|
Leber N, Kaps L, Yang A, Aslam M, Giardino M, Klefenz A, Choteschovsky N, Rosigkeit S, Mostafa A, Nuhn L, Schuppan D, Zentel R. α-Mannosyl-Functionalized Cationic Nanohydrogel Particles for Targeted Gene Knockdown in Immunosuppressive Macrophages. Macromol Biosci 2019. [DOI: 10.1002/mabi.201970019] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
9
|
Haehnel PS, Swoboda S, Lehmann N, Rosigkeit S, Gothe H, Sasca DI, Strand D, Theobald M, Roukos V, Bockamp E, Kindler T. Abstract 267: Targeting the alt-NHEJ DNA repair pathway selectively sensitizes KRAS-mutant cancer cells to chemotherapy. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Genomic instability is considered as a hallmark of human cancer. Whereas the oncogene-induced emergence of genetic lesions caused by increased levels of reactive oxygen species (ROS) and/or replicative stress is well characterised, the impact of defined driver mutations on individual DNA damage response and repair pathways is poorly understood. Recently, we have shown that oncogenic Kirsten-rat sarcoma (KRAS) dysregulates the repair of DNA double-strand breaks (DSB) and shifts the balance from canonical non-homologous end-joining (c-NHEJ) towards the highly error-prone alternative-NHEJ (alt-NHEJ) repair pathway by upregulation of XRCC1, PARP1 and DNA ligase 3α (Lig3α).
In this study, we wanted to investigate, whether KRAS-mutant (KRASmut) lung cancer cells rely on alt-NHEJ to repair genotoxic stress-induced DSBs. In addition, we addressed the question whether targeting essential component of the alt-NHEJ pathways sensitises KRASmut cells toward genotoxic agents.
The presence of oncogenic KRAS associates with increased expression of essential components of the error-prone alt-NHEJ pathway and causes enhanced alt-NHEJ activity compared to KRAS-wild-type (KRASwt) lung cancer cells as revealed by in vivo host cell reactivation assays. Pharmacologic inhibition of PARP, which has been shown to promote end joining by alt-NHEJ, resulted in increased apoptosis upon combined treatment with standard genotoxic agents in KRASmut cells but not KRASwt cells. Moreover, mice bearing tumor xenografts derived from KRASmut lung cancer cell lines but not KRASwt tumors experienced attenuated tumor growth and longer overall survival upon treatment with the PARP-inhibitor Olaparib and chemotherapy compared to single agent therapy, respectively. Similar results were obtained using a genetically modified mouse model of inducible, KRASmut-dependent lung cancer. Mice bearing KRASmut lung tumors showed a significantly reduced tumor burden when treated with the combination therapy of Olaparib and the topoisomerase II inhibitor VP-16 compared to animals treated only with single agents alone. Mechanistically, the DNA damage sensor protein KU70 is trapped in the cytoplasm in a KRASmut-dependent manner. siRNA-mediated knockdown of KRAS caused a shift of KU70 into the nucleus allowing access of KU70 to DSBs and to initiate DNA repair via the c-NHEJ repair pathway.
Our data provide evidence for a novel synthetic lethal interaction between oncogenic KRAS and DNA damage repair. Targeting components of the alt-NHEJ represents a so far not recognized therapeutic strategy to induce synthetic vulnerability in cells harbouring otherwise non-druggable KRAS mutations.
Citation Format: Patricia S. Haehnel, Sarah Swoboda, Nadine Lehmann, Sebastian Rosigkeit, Hernike Gothe, Danial I. Sasca, Dennis Strand, Matthias Theobald, Vassilis Roukos, Ernesto Bockamp, Thomas Kindler. Targeting the alt-NHEJ DNA repair pathway selectively sensitizes KRAS-mutant cancer cells to chemotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 267.
Collapse
|
10
|
Leber N, Kaps L, Yang A, Aslam M, Giardino M, Klefenz A, Choteschovsky N, Rosigkeit S, Mostafa A, Nuhn L, Schuppan D, Zentel R. α‐Mannosyl‐Functionalized Cationic Nanohydrogel Particles for Targeted Gene Knockdown in Immunosuppressive Macrophages. Macromol Biosci 2019; 19:e1900162. [DOI: 10.1002/mabi.201900162] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2019] [Indexed: 01/02/2023]
Affiliation(s)
- Nadine Leber
- Institutes of Organic ChemistryJohannes Gutenberg‐University of Mainz Duesbergweg 10‐14 55128 Mainz Germany
| | - Leonard Kaps
- Institute of Translational Immunology and Research Center for ImmunotherapyUniversity Medical Center of the Johannes Gutenberg‐University Mainz Obere Zahlbacher Str. 63 55131 Mainz Germany
| | - Aiting Yang
- Institute of Translational Immunology and Research Center for ImmunotherapyUniversity Medical Center of the Johannes Gutenberg‐University Mainz Obere Zahlbacher Str. 63 55131 Mainz Germany
| | - Misbah Aslam
- Institute of Translational Immunology and Research Center for ImmunotherapyUniversity Medical Center of the Johannes Gutenberg‐University Mainz Obere Zahlbacher Str. 63 55131 Mainz Germany
- Department of MicrobiologyShaheed Benazir Bhutto Women University LARAMA, Charsadda Road, Peshawar, Pakistan
| | - Mariacristina Giardino
- Institute of Translational Immunology and Research Center for ImmunotherapyUniversity Medical Center of the Johannes Gutenberg‐University Mainz Obere Zahlbacher Str. 63 55131 Mainz Germany
| | - Adrian Klefenz
- Institute of Translational Immunology and Research Center for ImmunotherapyUniversity Medical Center of the Johannes Gutenberg‐University Mainz Obere Zahlbacher Str. 63 55131 Mainz Germany
| | - Niklas Choteschovsky
- Institute of Translational Immunology and Research Center for ImmunotherapyUniversity Medical Center of the Johannes Gutenberg‐University Mainz Obere Zahlbacher Str. 63 55131 Mainz Germany
| | - Sebastian Rosigkeit
- Institute of Translational Immunology and Research Center for ImmunotherapyUniversity Medical Center of the Johannes Gutenberg‐University Mainz Obere Zahlbacher Str. 63 55131 Mainz Germany
| | - Asmaa Mostafa
- Institute of Translational Immunology and Research Center for ImmunotherapyUniversity Medical Center of the Johannes Gutenberg‐University Mainz Obere Zahlbacher Str. 63 55131 Mainz Germany
| | - Lutz Nuhn
- Max‐Planck‐Institute for Polymer Research Ackermannweg 10 55128 Mainz Germany
| | - Detlef Schuppan
- Institute of Translational Immunology and Research Center for ImmunotherapyUniversity Medical Center of the Johannes Gutenberg‐University Mainz Obere Zahlbacher Str. 63 55131 Mainz Germany
- Division of GastroenterologyBeth Israel Deaconess Medical Center, Harvard Medical School 330 Brookline Avenue Boston MA 02215 USA
| | - Rudolf Zentel
- Institutes of Organic ChemistryJohannes Gutenberg‐University of Mainz Duesbergweg 10‐14 55128 Mainz Germany
| |
Collapse
|
11
|
Rosigkeit S, Meng M, Grunwitz C, Gomes P, Kreft A, Hayduk N, Heck R, Pickert G, Ziegler K, Abassi Y, Röder J, Kaps L, Vascotto F, Beissert T, Witzel S, Kuhn A, Diken M, Schuppan D, Sahin U, Haas H, Bockamp E. Monitoring Translation Activity of mRNA-Loaded Nanoparticles in Mice. Mol Pharm 2018; 15:3909-3919. [DOI: 10.1021/acs.molpharmaceut.8b00370] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
| | - Martin Meng
- BioNTech RNA Pharmaceuticals GmbH, 55131 Mainz, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Andreas Kuhn
- BioNTech RNA Pharmaceuticals GmbH, 55131 Mainz, Germany
| | - Mustafa Diken
- BioNTech RNA Pharmaceuticals GmbH, 55131 Mainz, Germany
- TRON gGmbH, 55131 Mainz, Germany
| | - Detlef Schuppan
- Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, United States
| | - Ugur Sahin
- BioNTech RNA Pharmaceuticals GmbH, 55131 Mainz, Germany
- TRON gGmbH, 55131 Mainz, Germany
| | - Heinrich Haas
- BioNTech RNA Pharmaceuticals GmbH, 55131 Mainz, Germany
| | | |
Collapse
|
12
|
Foerster F, Boegel S, Heck R, Pickert G, Rüssel N, Rosigkeit S, Bros M, Strobl S, Kaps L, Aslam M, Diken M, Castle J, Sahin U, Tuettenberg A, Bockamp E, Schuppan D. Enhanced protection of C57 BL/6 vs Balb/c mice to melanoma liver metastasis is mediated by NK cells. Oncoimmunology 2017; 7:e1409929. [PMID: 29632723 PMCID: PMC5889278 DOI: 10.1080/2162402x.2017.1409929] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2017] [Revised: 11/07/2017] [Accepted: 11/21/2017] [Indexed: 01/26/2023] Open
Abstract
The B16F10 murine melanoma cell line displays a low expression of MHC class I molecules favoring immune evasion and metastases in immunocompetent C57 BL/6 wild-type mice. Here, we generated metastases to the liver, an organ that is skewed towards immune tolerance, by intrasplenic injection of B16F10 cells in syngeneic C57 BL/6 compared to allogeneic Balb/c mice. Surprisingly, Balb/c mice, which usually display a pronounced M2 macrophage and Th2 T cell polarization, were ∼3 times more susceptible to metastasis than C57 BL/6 mice, despite a much higher M1 and Th1 T cell immune response. The anti-metastatic advantage of C57 BL/6 mice could be attributed to a more potent NK-cell mediated cytotoxicity against B16F10 cells. Our findings highlight the role of NK cells in innate anti-tumor immunity in the context of the liver – particularly against highly aggressive MHC I-deficient cancer cells. Moreover, the B16F10 model of melanoma liver metastasis is suited for developing novel therapies targeting innate NK cell related immunity in liver metastases and liver cancer.
Collapse
Affiliation(s)
- Friedrich Foerster
- First Department of Medicine, University Medical Center Mainz, Mainz, Germany.,Institute of Translational Immunology and Research Center for Immunotherapy, University Medical Center Mainz, Mainz, Germany
| | - Sebastian Boegel
- TRON - Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH, Mainz, Germany
| | - Rosario Heck
- Institute of Translational Immunology and Research Center for Immunotherapy, University Medical Center Mainz, Mainz, Germany
| | - Geetha Pickert
- Institute of Translational Immunology and Research Center for Immunotherapy, University Medical Center Mainz, Mainz, Germany
| | - Nina Rüssel
- Institute of Translational Immunology and Research Center for Immunotherapy, University Medical Center Mainz, Mainz, Germany
| | - Sebastian Rosigkeit
- Institute of Translational Immunology and Research Center for Immunotherapy, University Medical Center Mainz, Mainz, Germany
| | - Matthias Bros
- Department of Dermatology, University Medical Center Mainz, Mainz, Germany
| | - Stephanie Strobl
- Institute of Translational Immunology and Research Center for Immunotherapy, University Medical Center Mainz, Mainz, Germany
| | - Leonard Kaps
- Institute of Translational Immunology and Research Center for Immunotherapy, University Medical Center Mainz, Mainz, Germany
| | - Misbah Aslam
- Institute of Translational Immunology and Research Center for Immunotherapy, University Medical Center Mainz, Mainz, Germany
| | - Mustafa Diken
- TRON - Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH, Mainz, Germany
| | - John Castle
- TRON - Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH, Mainz, Germany
| | - Ugur Sahin
- TRON - Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH, Mainz, Germany
| | - Andrea Tuettenberg
- Department of Dermatology, University Medical Center Mainz, Mainz, Germany
| | - Ernesto Bockamp
- Institute of Translational Immunology and Research Center for Immunotherapy, University Medical Center Mainz, Mainz, Germany
| | - Detlef Schuppan
- Institute of Translational Immunology and Research Center for Immunotherapy, University Medical Center Mainz, Mainz, Germany.,Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
13
|
Kaps L, Nuhn L, Aslam M, Brose A, Foerster F, Rosigkeit S, Renz P, Heck R, Kim YO, Lieberwirth I, Schuppan D, Zentel R. In Vivo Gene-Silencing in Fibrotic Liver by siRNA-Loaded Cationic Nanohydrogel Particles. Adv Healthc Mater 2015; 4:2809-15. [PMID: 26627192 DOI: 10.1002/adhm.201500826] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2015] [Indexed: 12/20/2022]
Abstract
Cationic nanohydrogel particles loaded with anti-Col1α1 siRNA suppress collagen synthesis and deposition in fibrotic mice: Systemically administered 40 nm sized nanogel particles accumulate in collagen-expressing cells in the liver. Their siRNA payload induces a sequence specific in vivo gene knockdown affording an efficient antifibrotic effect in mice with liver fibrosis.
Collapse
Affiliation(s)
- Leonard Kaps
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI); University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
| | - Lutz Nuhn
- Institute of Organic Chemistry; Johannes Gutenberg-University Mainz; Duesbergweg 10-14 55128 Mainz Germany
- Department of Pharmaceutics; Ghent University; Ottergemsesteenweg 460 9000 Ghent Belgium
| | - Misbah Aslam
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI); University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
| | - Alexander Brose
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI); University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
| | - Friedrich Foerster
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI); University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
- Department of Medicine I (Gastroenterology Hepatology, and Nephrology); University Medical Center of Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
| | - Sebastian Rosigkeit
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI); University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
| | - Patricia Renz
- Max Planck Institute for Polymer Research; Ackermannweg 10 55128 Mainz Germany
| | - Rosario Heck
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI); University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
| | - Yong Ook Kim
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI); University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
| | - Ingo Lieberwirth
- Max Planck Institute for Polymer Research; Ackermannweg 10 55128 Mainz Germany
| | - Detlef Schuppan
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI); University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
- Division of Gastroenterology; Beth Israel Deaconess Medical Center; Harvard Medical School; 330 Brookline Avenue Boston MA 02215 USA
| | - Rudolf Zentel
- Institute of Organic Chemistry; Johannes Gutenberg-University Mainz; Duesbergweg 10-14 55128 Mainz Germany
| |
Collapse
|
14
|
Kaps L, Nuhn L, Aslam M, Brose A, Foerster F, Rosigkeit S, Renz P, Heck R, Kim YO, Lieberwirth I, Schuppan D, Zentel R. Nanomedicine: In Vivo Gene-Silencing in Fibrotic Liver by siRNA-Loaded Cationic Nanohydrogel Particles (Adv. Healthcare Mater. 18/2015). Adv Healthc Mater 2015. [DOI: 10.1002/adhm.201570101] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Leonard Kaps
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI); University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
| | - Lutz Nuhn
- Institute of Organic Chemistry; Johannes Gutenberg-University Mainz; Duesbergweg 10-14 55128 Mainz Germany
- Department of Pharmaceutics; Ghent University; Ottergemsesteenweg 460 9000 Ghent Belgium
| | - Misbah Aslam
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI); University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
| | - Alexander Brose
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI); University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
| | - Friedrich Foerster
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI); University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
- Department of Medicine I (Gastroenterology Hepatology, and Nephrology); University Medical Center of Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
| | - Sebastian Rosigkeit
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI); University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
| | - Patricia Renz
- Max Planck Institute for Polymer Research; Ackermannweg 10 55128 Mainz Germany
| | - Rosario Heck
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI); University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
| | - Yong Ook Kim
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI); University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
| | - Ingo Lieberwirth
- Max Planck Institute for Polymer Research; Ackermannweg 10 55128 Mainz Germany
| | - Detlef Schuppan
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI); University Medical Center of the Johannes Gutenberg-University Mainz; Langenbeckstraße 1 55101 Mainz Germany
- Division of Gastroenterology; Beth Israel Deaconess Medical Center; Harvard Medical School; 330 Brookline Avenue Boston MA 02215 USA
| | - Rudolf Zentel
- Institute of Organic Chemistry; Johannes Gutenberg-University Mainz; Duesbergweg 10-14 55128 Mainz Germany
| |
Collapse
|